Acorda wasted no time getting down to business following its buyout of Civitas Therapeutics Inc. in October, enrolling the first patient in the pivotal study of CVT-301, an inhaled version of levodopa designed specifically to reduce motor fluctuation – i.e., “off” episodes – in Parkinson’s disease patients.